EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-Metaanalyse

Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis

Keiichiro Mori iD, Takafumi Yanagisawa iD, Wataru Fukuokaya iD, Kosuke Iwatani, Akihiro Matsukawa iD, Satoshi Katayama iD, Benjamin Pradere, Ekaterina Laukhtina iD, Pawel Rajwa, Marco Moschini iD, Simone Albisinni iD, Wojciech Krajewski und 12 weitere

International Journal of Urology · 2024-01 · 31 (1) · 25-31

DOI: 10.1111/iju.15319 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Urology, online erschienen am 15.10.2023. Verfasst von Keiichiro Mori und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Kidney Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adjuvant immune checkpoint inhibitor therapies have radically altered the treatment landscape for renal cell carcinoma and urothelial carcinoma. However, studies have reported negative data regarding adjuvant immune checkpoint inhibitor therapies. Thus, this study aimed to assess the role of adjuvant immune checkpoint inhibitor therapy for both renal cell carcinoma and urothelial carcinoma. A systematic review and network meta‐analysis were conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement. Multiple databases were searched for articles published as of February 2023. Studies were deemed eligible if they evaluated disease‐free survival in patients with renal cell carcinoma and urothelial carcinoma receiving adjuvant immune checkpoint inhibitor therapy. Five studies met the inclusion criteria. In a network meta‐analysis, pembrolizumab was shown to be the most effective regimen for patients with renal cell carcinoma, whereas nivolumab was found to be the most effective regimen for patients with urothelial carcinoma. Additionally, these results were consistently observed in a sub‐analysis of the T stage. The present analysis provides findings that support the usefulness of adjuvant nivolumab therapy in urothelial carcinoma and adjuvant pembrolizumab therapy in renal cell carcinoma, in agreement with the currently available guidelines. However, the caveat is that the randomized controlled trials included in this analysis differed in important respects despite being similar in study design. Therefore, with these differences in mind, care needs to be taken when selecting patients for these immune checkpoint inhibitor therapies to maximize their benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellCarcinoma, Transitional CellUrinary Bladder NeoplasmsKidney NeoplasmsHumansNivolumabImmune Checkpoint InhibitorsImmunotherapyAdjuvants, ImmunologicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

adjuvant immunotherapyrenal cell carcinomaurothelial carcinoma

Substanzen

NivolumabImmune Checkpoint InhibitorsAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
  • Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
  • Department of Urology, Medical University of Silesia, Zabrze, Poland.

ORCID-Profile: Keiichiro Mori, Takafumi Yanagisawa, Wataru Fukuokaya, Akihiro Matsukawa, Satoshi Katayama, Ekaterina Laukhtina, Marco Moschini, Simone Albisinni, Francesco Del Giudice, Jeremy Teoh, Fumihiko Urabe, Shunsuke Tsuzuki, Jun Miki, Takahiro Kimura

Zitieren

APA

Mori, K., Yanagisawa, T., Fukuokaya, W., Iwatani, K., Matsukawa, A., Katayama, S., Pradere, B., Laukhtina, E., Rajwa, P., Moschini, M., Albisinni, S., Krajewski, W., Cimadamore, A., Del Giudice, F., Teoh, J., Urabe, F., Kimura, S., Murakami, M., Tsuzuki, S., …, & European Association of Urology-Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU) (2024). Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis. International Journal of Urology, 31(1), 25-31. https://doi.org/10.1111/iju.15319

Vancouver

Mori K, Yanagisawa T, Fukuokaya W, Iwatani K, Matsukawa A, Katayama S, et al. Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis. International Journal of Urology. 2024;31(1):25-31. doi:10.1111/iju.15319

BibTeX
@article{Mori2024,
  author = {Mori, Keiichiro and Yanagisawa, Takafumi and Fukuokaya, Wataru and Iwatani, Kosuke and Matsukawa, Akihiro and Katayama, Satoshi and Pradere, Benjamin and Laukhtina, Ekaterina and Rajwa, Pawel and Moschini, Marco and Albisinni, Simone and Krajewski, Wojciech and Cimadamore, Alessia and Del Giudice, Francesco and Teoh, Jeremy and Urabe, Fumihiko and Kimura, Shoji and Murakami, Masaya and Tsuzuki, Shunsuke and Miki, Jun and Miki, Kenta and Shariat, Shahrokh F and Kimura, Takahiro and European Association of Urology-Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU), European Association of Urology-Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)},
  title = {Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis},
  journal = {International Journal of Urology},
  year = {2024},
  volume = {31},
  number = {1},
  pages = {25--31},
  doi = {10.1111/iju.15319}
}
Kostenlos starten →